Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study

Herbst, R.S.
Garon, E.B.
Kim, D.W.
Cho, B.C.
Perez-Gracia, J.L.
Han, J.Y.
Arvis, C.D.
Majem, M.
Forster, M.D.
Monnet, I.
Novello, S.
Szalai, Z.
Gubens, M.A.
Su, W.C.
Ceresoli, G.L.
Samkari, A.
Jensen, E.H.
Lubiniecki, G.M.
Baas, P.

May 2020

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in p...

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

Stephen V. Liu, MD
Pragya Rai, PhD
Dong Wang, PhD
Xiaohan Hu, PhD, MPH
Paul Otto Schwarzenberger, MD

February 2023

Introduction: Pembrolizumab plus carboplatin and (nab-)paclitaxel (pembrolizumab-chemotherapy) is cu...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population

Jiménez Galán, Rocío
Prado-Mel, Elena
Pérez-Moreno, María Antonia
Caballano-Infantes, Estefanía
Flores Moreno, Sandra

March 2022

This article belongs to the Section Cancer Biology.[Simple Summary] Monotherapy with pembrolizumab i...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Reck, M
Rodríguez-Abreu, D
Robinson, AG
Hui, R
Csőszi, T
Fülöp, A
Gottfried, M
Peled, N
Tafreshi, A
Cuffe, S
O'Brien, M
Rao, S
Hotta, K
Leal, TA
Riess, JW
Jensen, E
Zhao, B
Pietanza, MC
Brahmer, JR

April 2021

Purpose We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non...

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Borghaei, Hossein
Langer, Corey J.
Gadgeel, Shirish
Papadimitrakopoulou, Vassiliki A.
Patnaik, Amita
Powell, Steven F.
Gentzler, Ryan D.
Martins, Renato G.
Stevenson, James P.
Jalal, Shadia I.
Panwalkar, Amit
Yang, James Chih-Hsin
Gubens, Matthew
Sequist, Lecia V.
Awad, Mark M.
Fiore, Joseph
Saraf, Sanatan
Keller, Steven
Gandhi, Leena

January 2018

Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizum...

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study

Herbst, R.S.
Garon, E.B.
Kim, D.W.
Cho, B.C.
Perez-Gracia, J.L.
Han, J.Y.
Arvis, C.D.
Majem, M.
Forster, M.D.
Monnet, I.
Novello, S.
Szalai, Z.
Gubens, M.A.
Su, W.C.
Ceresoli, G.L.
Samkari, A.
Jensen, E.H.
Lubiniecki, G.M.
Baas, P.

May 2020

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in p...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study

Herbst, R.S.
Garon, E.B.
Kim, D.W.
Cho, B.C.
Perez-Gracia, J.L.
Han, J.Y.
Arvis, C.D.
Majem, M.
Forster, M.D.
Monnet, I.
Novello, S.
Szalai, Z.
Gubens, M.A.
Su, W.C.
Ceresoli, G.L.
Samkari, A.
Jensen, E.H.
Lubiniecki, G.M.
Baas, P.

May 2020

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in p...

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

Stephen V. Liu, MD
Pragya Rai, PhD
Dong Wang, PhD
Xiaohan Hu, PhD, MPH
Paul Otto Schwarzenberger, MD

February 2023

Introduction: Pembrolizumab plus carboplatin and (nab-)paclitaxel (pembrolizumab-chemotherapy) is cu...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer

Gadgeel S.
Rodriguez-Abreu D.
Speranza G.
Esteban E.
Felip E.
Domine M.
Hui R.
Hochmair M. J.
Clingan P.
Powell S. F.
Yee-Shan Cheng S.
Bischoff H. G.
Peled N.
Grossi F.
Jennens R. R.
Reck M.
Garon E. B.
Novello S.
Rubio-Viqueira B.
Boyer M.
Kurata T.
Gray J. E.
Yang J.
Bas T.
Pietanza M. C.
Garassino M. C.

January 2020

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved ove...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population

Jiménez Galán, Rocío
Prado-Mel, Elena
Pérez-Moreno, María Antonia
Caballano-Infantes, Estefanía
Flores Moreno, Sandra

March 2022

This article belongs to the Section Cancer Biology.[Simple Summary] Monotherapy with pembrolizumab i...

Does pembrolizumab have an effect on prolonging overall survival in patients with non-small cell lung cancer expressing programmed death ligand-1 (PD-L1)?

Song, Ha Y

January 2018

Objective: The objective of this selective EBM review is to determine whether or not pembrolizumab h...

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Reck, M
Rodríguez-Abreu, D
Robinson, AG
Hui, R
Csőszi, T
Fülöp, A
Gottfried, M
Peled, N
Tafreshi, A
Cuffe, S
O'Brien, M
Rao, S
Hotta, K
Leal, TA
Riess, JW
Jensen, E
Zhao, B
Pietanza, MC
Brahmer, JR

April 2021

Purpose We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non...

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Borghaei, Hossein
Langer, Corey J.
Gadgeel, Shirish
Papadimitrakopoulou, Vassiliki A.
Patnaik, Amita
Powell, Steven F.
Gentzler, Ryan D.
Martins, Renato G.
Stevenson, James P.
Jalal, Shadia I.
Panwalkar, Amit
Yang, James Chih-Hsin
Gubens, Matthew
Sequist, Lecia V.
Awad, Mark M.
Fiore, Joseph
Saraf, Sanatan
Keller, Steven
Gandhi, Leena

January 2018

Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizum...

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study

Herbst, R.S.
Garon, E.B.
Kim, D.W.
Cho, B.C.
Perez-Gracia, J.L.
Han, J.Y.
Arvis, C.D.
Majem, M.
Forster, M.D.
Monnet, I.
Novello, S.
Szalai, Z.
Gubens, M.A.
Su, W.C.
Ceresoli, G.L.
Samkari, A.
Jensen, E.H.
Lubiniecki, G.M.
Baas, P.

May 2020

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in p...

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Reck, Martin
Paz-Ares, Luis G.
de Marinis, Filippo
Molinier, Olivier
Sahoo, Tarini Prasad
Laack, Eckart
John, William
Zimmermann, Annamaria H.
Visseren-Grul, Carla
Gridelli, Cesare

February 2014

Introduction:The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance sig...

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study

Herbst, R.S.
Garon, E.B.
Kim, D.W.
Cho, B.C.
Perez-Gracia, J.L.
Han, J.Y.
Arvis, C.D.
Majem, M.
Forster, M.D.
Monnet, I.
Novello, S.
Szalai, Z.
Gubens, M.A.
Su, W.C.
Ceresoli, G.L.
Samkari, A.
Jensen, E.H.
Lubiniecki, G.M.
Baas, P.

May 2020

PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in p...

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

Stephen V. Liu, MD
Pragya Rai, PhD
Dong Wang, PhD
Xiaohan Hu, PhD, MPH
Paul Otto Schwarzenberger, MD

February 2023

Introduction: Pembrolizumab plus carboplatin and (nab-)paclitaxel (pembrolizumab-chemotherapy) is cu...

Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

Abstract

Extracted data

Real-World Maintenance Therapy and Survival Outcomes for Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA

Abstract

Extracted data

Related items

Related items